Homeopathic Materia Medica Of Clinical Immunology

The vision of Physiological Regulating Medicine on the use of physiological low doses of Hormones, Cytokines, Neuropeptides and Growth Factors

---

JERÔME MALZAC

Physiological Regulating Medicine is based on a revolutionary idea in the medical field: restoring the initial physiological conditions of a sick body by using the same biological molecules that are usually present in the body and which control and guide its functions in healthy conditions.

To be precise, these molecules are very well known and extensively studied in Molecular Biology, and it is no mere chance that they are called messenger molecules – substances that can convey the “right instructions” for correct function to the various cells of the body.

These molecules include Neuropeptides (Nervous System messengers), hormones (Endocrine System messengers), cytokines (Immune System messengers).

There are also growth factors, which are essential tissue regulating and stimulating molecules. It has been acknowledged that these substances play a decisive role in determining either health or disease, and today it has been ascertained that every disease is the expression of changes in concentrations – either of an increase or of a reduction – of these substances. All international medical research is focusing on the study of messenger molecules; the positive (healing) or negative (disease) fate of several pathological conditions depends on them and on the possibility of using them for therapeutic purposes.

Every disease is the expression and consequence of changes in messenger molecule concentrations

JERÔME MALZAC

For instance, correcting Immune System alterations through the use of cytokines and en- docrine diseases with hormones is one of the most fascinating and innovative objectives of research centered on applying Molecular Biology to Medicine. But the clinical application of this know-how has always come to a standstill when faced with the side effects caused by the high doses of these substances that have been routinely used until today.

The pharmaceutical technique known as SKA (Sequential Kinetic Activation) enables the administration of LOW DOSES OF HORMONES, NEUROPEPTIDES, CYTOKINES AND GROWTH FACTORS to achieve the same therapeutic results as high doses but without any side effects.

SKA (Sequential Kinetic Activation)

It is a sophisticated DRUG DELIVERY SYSTEM that ensures efficacy of molecular concentrations below the minimal effective dose.

In November 2009 the prestigious international scientific review Pulmonary Pharmacology & Therapeutics [22 (2009) 497-510] published the article Low dose oral administration of cytokines for treatment of allergic asthma. The paper enlarged on the effects of low doses of SKA-activated cytokines in the treatment of allergic asthma, proving in a clear, evident and especially reproducible manner that the low doses administered during the study produced the same effects as high doses in changing a series of clinical and laboratory parameters typical of the allergic condition. 

The SKA Method opens a new era in options for the clinical use of messenger molecules and concretises the “scientific dream” of using biological molecules, such as cytokines, hormones and neuropeptides, in low doses (the only doses that can avoid side effects).

A new frontier has most likely been set for pharmaceutical industries and in the field of Molecular Biology, and both Italian researchers and the Italian industry are paving the way in this sector.

Cytokines

Low physiological doses of cytokines activated with the SKA procedure are marketed in a hydroalcoholic solution in 30 ml bottles. The drug concentration is in picograms/ml, which corresponds to a homeopathic dilution of 4CH1.

DIRECTIONS 

The standard posology is 20 drops twice a day. Sublingual administration is recommended.

THERAPEUTIC PROTOCOLS

The duration of therapy differs depending on the clinical condition and on the gravity of the disease.

Chronic diseases usually require the administration of treatment cycles with minimum du- ration of 2 months. They can be repeated, preferably after a 15-day suspension.

In acute diseases therapy is continued until remission of symptoms. At times a massive dose therapy can be applied with 10 drops every 20 minutes for maximum 2 hours.

THERAPEUTIC STRATEGY

Cytokines can be prescribed following two trends.

 According to an aetiological decisional process:

• if the pathological condition is the expression of a down-regulation (deficiency) of a certain cytokine, the same cytokine will be used;
• if the pathological condition is the expression of an up-regulation (excess) of a certain cytokine, the so-called “opposing cytokine” will be used.

 According to a symptomatological decisional process:

• the cytokine is prescribed to suit the symptoms of the patient.

PRESCRIPTION ACCORDING TO THE AETIOLOGICAL DECISIONAL PROCESS

Prescription according to the symptomatological decision process

HORMONES & NEUROPEPTIDES

Low physiological doses of hormones activated with the SKA procedure are marketed in a hydroalcoholic solution in 30 ml bottles. The drug concentration is in picograms/ml, which corresponds to the homeopathic dilution of 4CH for some (Beta-Endorphin, Melatonin, Somatostatin), and in nanograms/ml, corresponding to the homeopathic dilution of 6DH for others.

DIRECTIONS

The standard posology is 20 drops twice a day. Sublingual administration is recommended.

THERAPEUTIC PROTOCOLS

The duration of treatment differs depending on the clinical condition and on the gravity of the disease.

Chronic diseases usually require the administration of treatment cycles with minimum du- ration of 2 months. They can be repeated, preferably after a 15-day suspension.

In acute diseases therapy is continued until remission of symptoms. At times a massive dose therapy can be applied with 10 drops every 20 minutes for maximum 2 hours.

THERAPEUTIC STRATEGY

Hormones and neuropeptides can be prescribed following two trends.

 According to an aetiological decisional process:

• if the pathological condition is the expression of a down-regulation (deficiency) of a certain hormone or neuropeptide, the same hormone will be used;

• If the pathological condition is the expression of an up-regulation (excess) of a certain hormone, the so-called “opposing hormone” will be used consistently with the physiology of negative feedback.

 According to a symptomatological decisional process:

• the hormone is prescribed to suit the symptoms of the patient.

PRESCRIPTION ACCORDING TO THE AETIOLOGICAL DECISIONAL PROCESS

Prescription according to the symptomatological decision process

GROWTH FACTORS

Low physiological doses of growth factors activated with the SKA procedure are marketed in a hydroalcoholic solution of 30 ml bottles. The drug concentration is in picograms/ml, which corresponds to a homeopathic dilution of 4CH.

DIRECTIONS 

The standard posology is 20 drops twice a day. Sublingual administration is recommended.

THERAPEUTIC PROTOCOLS 

The duration of therapy differs depending on the clinical condition and on the gravity of the disease.

Chronic diseases usually require the administration of treatment cycles with minimum du- ration of 2 months. They can be repeated, preferably after a 15-day suspension.

In acute diseases therapy is continued until remission of symptoms. At times a massive dose therapy can be applied with 10 drops every 20 minutes for maximum 2 hours.

THERAPEUTIC STRATEGY

Growth factors can be prescribed following two trends.

 According to an aetiological decisional process:

• if the pathological condition is the expression of a down-regulation (deficiency) of a certain growth factor, the same growth factor will be used.

 According to a symptomatological decisional process:

• the growth factor is prescribed to suit the symptoms of the patient.

Prescription according to the symptomatological decision process

MATERIA MEDICA